| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sara Medved, Zvonimir Ostojić, Hrvoje Jurin, Vesna Medve. Takotsubo cardiomyopathy after the first electroconvulsive therapy regardless of adjuvant beta-blocker use: a case report and literature review. Croatian medical journal. vol 59. issue 6. 2019-02-11. PMID:30610773. |
we describe a case of a 40-year-old male patient, with a history of schizophrenia and heavy caffeine and nicotine use, treated for acute psychotic episode with haloperidol and clozapine. |
2019-02-11 |
2023-08-13 |
Not clear |
| Brent Luu, George W Rodway, Elizabeth Ric. Should we be targeting sleep architecture to more effectively treat schizophrenia? JAAPA : official journal of the American Academy of Physician Assistants. vol 31. issue 12. 2019-01-30. PMID:30489392. |
this article discusses the use of polysomnography to characterize the sleeping patterns of patients diagnosed with schizophrenia and the positive influence of clozapine on sleep in patients with schizophrenia. |
2019-01-30 |
2023-08-13 |
Not clear |
| Hong Shen, Danyang Wu, Shanshan Wang, Mengjie Zhao, Wenbo Sun, Xiaozhou Zhu, Ning Zhang, Hui Yao, Qing Cui, Hong Xia. Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study. Basic & clinical pharmacology & toxicology. vol 123. issue 6. 2019-01-29. PMID:29938908. |
data were collected for 452 patients with eligible schizophrenia: 163 treated with clozapine, 186 treated with olanzapine, 47 treated with quetiapine and 56 receiving no medication. |
2019-01-29 |
2023-08-13 |
Not clear |
| Hong Shen, Danyang Wu, Shanshan Wang, Mengjie Zhao, Wenbo Sun, Xiaozhou Zhu, Ning Zhang, Hui Yao, Qing Cui, Hong Xia. Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study. Basic & clinical pharmacology & toxicology. vol 123. issue 6. 2019-01-29. PMID:29938908. |
this study is the first to confirm that aap administration, especially clozapine and olanzapine, could increase lp-pla2 levels and cvd risk, independent of drug-induced weight gain in schizophrenia. |
2019-01-29 |
2023-08-13 |
Not clear |
| Rusmir Softic, Alija Sutovic, Esmina Avdibegovic, Enes Osmanović, Elvir Bećirović, Mitra Mirković Hajduko. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy? Psychiatria Danubina. vol 27. issue 4. 2019-01-28. PMID:26609650. |
metabolic syndrome in schizophrenia - who is more to blame: fga polypharmacy or clozapine monotherapy? |
2019-01-28 |
2023-08-13 |
Not clear |
| Rusmir Softic, Alija Sutovic, Esmina Avdibegovic, Enes Osmanović, Elvir Bećirović, Mitra Mirković Hajduko. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy? Psychiatria Danubina. vol 27. issue 4. 2019-01-28. PMID:26609650. |
to establish the prevalence of metabolic syndrome and its parameters in group of patients with schizophrenia in polypharmacy - receiving first generation antipsychotics versus clozapine alone treated group. |
2019-01-28 |
2023-08-13 |
Not clear |
| Edith J Chau, Md Shaki Mostaid, Vanessa Cropley, Patrick McGorry, Christos Pantelis, Chad A Bousman, Ian P Everal. Downregulation of plasma SELENBP1 protein in patients with recent-onset schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 85. 2019-01-17. PMID:29577944. |
measurement of peripheral mrna levels showed no difference between treatment-resistant schizophrenia and healthy controls (p = 0.234) but clozapine plasma levels (p = 0.036) and duration of illness (p = 0.028) were positively correlated with mrna levels. |
2019-01-17 |
2023-08-13 |
Not clear |
| Belén Arranz, Marina Garriga, Clemente García-Rizo, Luis Sa. Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 2. 2019-01-14. PMID:29273271. |
clozapine use in patients with schizophrenia and a comorbid substance use disorder: a systematic review. |
2019-01-14 |
2023-08-13 |
Not clear |
| Selene Veerman, Peter Schulte, Lieuwe de Haa. Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia. Psychopharmacology. vol 234. issue 23-24. 2019-01-10. PMID:29038824. |
memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia. |
2019-01-10 |
2023-08-13 |
Not clear |
| Robert J Feeley, Bachaar Arnaout, Gihyun Yoo. Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder. Journal of clinical psychopharmacology. vol 37. issue 6. 2019-01-07. PMID:29028689. |
effective switch from clozapine to aripiprazole in treatment-resistant schizophrenia and comorbid alcohol use disorder. |
2019-01-07 |
2023-08-13 |
Not clear |
| Heeyoung Lee, Britney B Scolieri, Prabir K Mullic. Learned lessons from patients who take clozapine: A case study. Perspectives in psychiatric care. vol 54. issue 4. 2018-12-11. PMID:28926097. |
the purpose of this report is to provide clinical strategies to manage patients with schizophrenia taking clozapine. |
2018-12-11 |
2023-08-13 |
Not clear |
| David D Kim, Donna J Lang, Ric M Procyshyn, Melissa L Woodward, Kai Kaufman, Randall F White, William G Honer, Darren E R Warburto. Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia. Psychiatry research. vol 262. 2018-12-11. PMID:29407565. |
reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia. |
2018-12-11 |
2023-08-13 |
Not clear |
| Patricio Alb. [Treatment-resistant schizophrenia: Neutropenia with olanzapine and clozapine, and stabilization with two depot antipsychotics]. Vertex (Buenos Aires, Argentina). vol 28. issue 132. 2018-12-11. PMID:29522636. |
[treatment-resistant schizophrenia: neutropenia with olanzapine and clozapine, and stabilization with two depot antipsychotics]. |
2018-12-11 |
2023-08-13 |
Not clear |
| John Lally, Hana Al Kalbani, Amir Krivoy, Kieran C Murphy, Fiona Gaughran, James H MacCab. Hepatitis, Interstitial Nephritis, and Pancreatitis in Association With Clozapine Treatment: A Systematic Review of Case Series and Reports. Journal of clinical psychopharmacology. vol 38. issue 5. 2018-12-11. PMID:30059436. |
clozapine is the criterion standard in treatment-resistant schizophrenia. |
2018-12-11 |
2023-08-13 |
Not clear |
| Carolyn B McNabb, Roger J Tait, Meghan E McIlwain, Valerie M Anderson, John Suckling, Robert R Kydd, Bruce R Russel. Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia. Schizophrenia research. vol 195. 2018-11-26. PMID:29042073. |
resting-state functional mri data were obtained from 17 healthy controls as well as individuals with schizophrenia who responded well to first-line atypical antipsychotics (first-line responders; flr, n=18), had failed at least two trials of antipsychotics but responded to clozapine (treatment-resistant schizophrenia; trs, n=18), or failed at least two trials of antipsychotics and a trial of clozapine (ultra-treatment-resistant schizophrenia; utrs, n=16). |
2018-11-26 |
2023-08-13 |
Not clear |
| Fatemeh Behdani, Seyede Narjes Roudbaraki, Maryam Saberi-Karimian, Maryam Tayefi, Paria Hebrani, Amir Akhavanrezayat, Sadegh Vahabi Amlashi, Gordon A Ferns, Majid Ghayour-Mobarha. Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. Psychiatry research. vol 261. 2018-11-20. PMID:29329042. |
assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. |
2018-11-20 |
2023-08-13 |
human |
| Fatemeh Behdani, Seyede Narjes Roudbaraki, Maryam Saberi-Karimian, Maryam Tayefi, Paria Hebrani, Amir Akhavanrezayat, Sadegh Vahabi Amlashi, Gordon A Ferns, Majid Ghayour-Mobarha. Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. Psychiatry research. vol 261. 2018-11-20. PMID:29329042. |
we aimed to assess the efficacy of omega-3 fatty acids on metabolic and inflammatory indices in patients with schizophrenia who were taking clozapine and sodium valproate. |
2018-11-20 |
2023-08-13 |
human |
| Fatemeh Behdani, Seyede Narjes Roudbaraki, Maryam Saberi-Karimian, Maryam Tayefi, Paria Hebrani, Amir Akhavanrezayat, Sadegh Vahabi Amlashi, Gordon A Ferns, Majid Ghayour-Mobarha. Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. Psychiatry research. vol 261. 2018-11-20. PMID:29329042. |
our results showed omega-3 fa supplementation can improve some anthropometric indices in patients with schizophrenia who are taking clozapine pharmacotherapy. |
2018-11-20 |
2023-08-13 |
human |
| Marise W J Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophrenia research. vol 194. 2018-11-13. PMID:28351544. |
comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: a randomized fmri study. |
2018-11-13 |
2023-08-13 |
Not clear |
| Narjes Hendouei, Samaneh Farnia, Farhad Mohseni, Azadeh Salehi, Maedeh Bagheri, Faezeh Shadfar, Fatemeh Barzegar, Seyed Davood Hoseini, Jamshid Yazdani Charati, Fatemeh Shak. Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 103. 2018-11-13. PMID:29710513. |
therefore, in this study, we evaluated the level of oxidative stress parameters between patients treated with perphenazine, clozapine and risperidone and their relationship with schizophrenia symptoms' severity. |
2018-11-13 |
2023-08-13 |
Not clear |